|
1.
|
|
17 p, 742.8 KB |
Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease : A Multicentre Study of Geteccu
/
García García, María José (Universidad de Cantabria) ;
Rivero, Montserrat (Universidad de Cantabria) ;
Miranda Bautista, José (Hospital Universitario Gregorio Marañón) ;
Bastón Rey, Iria (Hospital Universitario Clínico de Santiago) ;
Mesonero, Francisco (Hospital Universitario Ramón y Cajal) ;
Leo Carnerero, Eduardo (Hospital Universitario Virgen del Rocío) ;
Casas Deza, Diego (Hospital Universitario Miguel Servet) ;
Cagigas Fernández, Carmen (Hospital Universitario Marqués de Valdecilla) ;
Martin Cardona, Albert (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
El Hajra, Ismael (Hospital Universitario Puerta de Hierro) ;
Hernández Aretxabaleta, Nerea (Hospital Universitario de Basurto) ;
Pérez Martínez, Isabel (Hospital Universitario Central de Asturias) ;
Fuentes Valenzuela, Esteban (Hospital Universitario Río Hortega) ;
Jiménez, Nuria (Hospital General Universitario de Elche) ;
Rubín de Célix, Cristina (Hospital Universitario de La Princesa) ;
Gutiérrez Casbas, Ana (Hospital General de Alicante) ;
Suárez Ferrer, Cristina (Hospital Universitario La Paz) ;
Huguet, José María (Hospital General Universitario de Valencia) ;
Fernández Clotet, Agnes (Hospital Clínic i Provincial de Barcelona) ;
González Vivó, María (Hospital del Mar (Barcelona, Catalunya)) ;
Del Val, Blanca (Hospital Rafael Méndez) ;
Castro Poceiro, Jesús (Hospital Sant Joan Despí-Moisès Broggi) ;
Melcarne, Luigi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Dueñas, Carmen (Hospital Universitario de Cáceres) ;
Izquierdo, Marta (Hospital Universitario de Cabueñes) ;
Monfort, David (Gastroenterology Department, Consorci Sanitari de Terrassa) ;
Bouhmidi, Abdel (Hospital de Santa Bárbara) ;
Ramírez De la Piscina, Patricia (Hospital Universitario Vitoria-Gastéiz) ;
Romero, Eva (Hospital Clínic Universitari (València)) ;
Molina, Gema (Hospital Arquitecto Marcide) ;
Zorrilla, Jaime (Hospital Universitario Gregorio Marañón) ;
Calvino Suárez, Cristina (Hospital Universitario Clínico de Santiago) ;
Sánchez, Eugenia (Hospital Universitario Ramón y Cajal) ;
Nuñez, Andrea (Hospital Universitario Virgen del Rocío) ;
Sierra, Olivia (Hospital Universitario Miguel Servet) ;
Castro, Beatriz (Universidad de Cantabria) ;
Zabana, Yamile (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
González Partida, Irene (Hospital Universitario Puerta de Hierro) ;
De la Maza, Saioa (Hospital Universitario de Basurto) ;
Castaño-García, Andrés (Hospital Universitario Central de Asturias) ;
Nájera Muñoz, Rodrigo (Hospital Universitario Río Hortega) ;
Sánchez Guillén, Luis (Hospital General Universitario de Elche) ;
Riat Castro, Micaela (Hospital Universitario de La Princesa) ;
Rueda, José Luis (Hospital Universitario La Paz) ;
Benítez, José Manuel (Hospital Reina Sofía) ;
Delgado Guillena, Pedro (Hospital General de Granollers) ;
Tardillo, Carlos (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Peña, Elena (Hospital Royo Villanova) ;
Frago Larramona, Santiago (Complejo Hospitalario de Soria) ;
Rodríguez Grau, María Carmen (Hospital Universitario de Henares) ;
Plaza, Rocío (Hospital Universitario Infanta Leonor) ;
Pérez Galindo, Pablo (Complejo Hospitalario Universitario de Pontevedra) ;
Martínez Cadilla, Jesús (Hospital Álvaro Cunqueiro (Vigo)) ;
Menchén, Luis (Hospital Universitario Gregorio Marañón) ;
Barreiro de-Acosta, Manuel (Hospital Universitario Clínico de Santiago) ;
Sánchez Aldehuelo, Rubén (Hospital Universitario Ramón y Cajal) ;
De la Cruz, María Dolores (Hospital Universitario Virgen del Rocío) ;
Lamuela, Luis Javier (Hospital Universitario Miguel Servet) ;
Marín, Ignacio (Hospital Universitario Gregorio Marañón) ;
Nieto García, Laura (Hospital Universitario Clínico de Santiago) ;
López San Román, Antonio (Hospital Universitario Ramón y Cajal) ;
Herrera, José Manuel (Hospital Universitario Virgen del Rocío) ;
Chaparro, María (Hospital Universitario de La Princesa) ;
P. Gisbert, Javier (Hospital Universitario de La Princesa) ;
Universitat Autònoma de Barcelona
Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. [...]
2021 -  10.3390/jcm10194402
Journal of clinical medicine, Vol. 10 (september 2021)
|
|
|
2.
|
|
19 p, 1.6 MB |
Strategies to design clinical studies to identify predictive biomarkers in cancer research
/
Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ;
Sanmamed, Miguel F. (Yale University School of Medicine) ;
Bosch, Ana (Lund University) ;
Patiño-Garcia, Ana (Clínica Universidad de Navarra) ;
Schalper, Kurt A. (Yale School of Medicine) ;
Segura, Victor (Universidad de Navarra) ;
Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Martín Jiménez, Miguel (Hospital Gregorio Marañón. Instituto de Investigación Sanitaria) ;
Fusco, Juan Pablo (Clínica Universidad de Navarra) ;
Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ;
Calvo, Alfonso (Universidad de Navarra) ;
Prior, Celia (Universidad de Navarra) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Pio, Ruben (Universidad de Navarra) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Gonzalez Hernandez, Alvaro (Clínica Universidad de Navarra) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Piulats, Jose María (Institut Català d'Oncologia) ;
Gurpide, Alfonso (Universidad de Navarra) ;
Andueza, Mapi (Clínica Universidad de Navarra) ;
de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ;
Pazo, Roberto (Hospital Universitario Miguel Servet (Saragossa)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nicolas, Pilar (Universidad del País Vasco) ;
Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ;
Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Pajares, María J. (Universidad de Navarra) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ;
Montuenga, Luis M. (Universidad de Navarra) ;
Melero, Ignacio (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 - 10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97
|
|
|
3.
|
|
14 p, 1.1 MB |
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
/
Navani, Vishal (University of Calgary) ;
Ernst, Matthew (University of Calgary) ;
Wells, J. Connor (BC Cancer Agency) ;
Yuasa, Takeshi (Japanese Foundation for Cancer Research) ;
Takemura, Kosuke (Japanese Foundation for Cancer Research) ;
Donskov, Frede (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Basappa, Naveen S. (University of Alberta) ;
Schmidt, Andrew (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Pal, Sumanta K. (City of Hope Comprehensive Cancer Center) ;
Meza, Luis (City of Hope Comprehensive Cancer Center) ;
Wood, Lori A. (Queen Elizabeth II Health Sciences Centre) ;
Ernst, D. Scott (London Regional Cancer Centre) ;
Szabados, Bernadett (Queen Mary University of London) ;
Powles, Thomas (Queen Mary University of London) ;
McKay, Rana R. (University of California) ;
Weickhardt, Andrew (Olivia Newton-John Cancer and Wellness Centre) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Kapoor, Anil (McMaster University (Canadà)) ;
Lee, Jae Lyun (University of Ulsan College of Medicine) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Heng, Daniel Y. C. (University of Calgary) ;
Universitat Autònoma de Barcelona
Do contemporary first-line therapy options for metastatic renal cell carcinoma (mRCC) have different likelihoods of objective imaging response (complete or partial response), and is objective imaging response associated with overall survival? In this cohort study involving 899 patients with mRCC, treatment with immune checkpoint blockade plus vascular endothelial growth factor receptor inhibitor combination therapies was more likely to be associated with objective imaging response than doublet immune checkpoint blockade therapy after adjustment for baseline demographic and clinical characteristics, including International Metastatic Renal Cell Carcinoma Database Consortium risk criteria. [...]
2022 - 10.1001/jamanetworkopen.2022.16379
JAMA network open, Vol. 5 (june 2022)
|
|
|
4.
|
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
|
5.
|
|
13 p, 2.0 MB |
Kidney Androgen-Regulated Protein (KAP) Transgenic Mice Are Protected Against High-Fat Diet Induced Metabolic Syndrome
/
de Quixano, Beatriz Bardaji (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Villena, Josep A. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Aranda Martín, Miguel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Brils, Gemma (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cuevas Alcalá, Antoni, (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hespel, Théana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lekuona, Haizea (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tornavaca, Olga (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Meseguer Navarro, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Metabolic Syndrome (MS) is reaching epidemic proportions with significant social and economical burden worldwide. Since the molecular basis of MS remains poorly defined, we investigated the impact of KAP, a kidney specific androgen-regulated gene, in the development of high fat-diet (hfd)-induced MS. [...]
2017 - 10.1038/s41598-017-16487-y
Scientific reports, Vol. 7 (november 2017)
|
|
|
6.
|
|
16 p, 3.7 MB |
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
/
Jiménez, Natalia (Fundació Clínic per a la Recerca Biomèdica) ;
Reig, Oscar (Hospital Clínic i Provincial de Barcelona) ;
Montalbo, Ruth (Fundació Clínic per a la Recerca Biomèdica) ;
Milà-Guasch, Maria (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Nadal-Dieste, Lluis (Hospital Clínic i Provincial de Barcelona) ;
Castellano, Giancarlo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lozano, Juan José (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Victoria, Iván (Hospital Clínic i Provincial de Barcelona) ;
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodriguez-Vida, Alejo (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Domènech, Montserrat (Medical Oncology Department, Fundació Althaia Manresa) ;
Sala-González, Núria (Hospital Universitari de Girona Doctor Josep Trueta) ;
Fernández, Pedro Luis (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Rodríguez-Carunchio, Leonardo (Hospital Clínic i Provincial de Barcelona) ;
Diaz, Sherley (Hospital Clínic i Provincial de Barcelona) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Marín-Aguilera, Mercedes (Hospital Clínic i Provincial de Barcelona) ;
Mellado, Begoña (Hospital Clínic i Provincial de Barcelona)
The prostatic tumor cells plasticity is involved in resistance to hormone-therapy, allowing these cells to survive despite androgen receptor inhibition. However, its role in taxanes resistance has not been fully established. [...]
2020 - 10.3389/fonc.2020.594023
Frontiers in Oncology, Vol. 10 (november 2020)
|
|
|
7.
|
|
|
8.
|
|
10 p, 595.1 KB |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
/
Wick, Antje (Heidelberg University Medical Center) ;
Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Burkholder, Tiana (Eli Lilly and Company) ;
Cleverly, Ann Louise (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Wang, Shuaicheng (BioStat Solutions (Estats Units)) ;
Lahn, Michael M.. (Eli Lilly and Company) ;
Guba, Susan C. (Eli Lilly and Company) ;
Capper, David (Charité - Universitätsmedizin Berlin) ;
Rodon Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The online version of this article contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579
|
|
|
9.
|
|
7 p, 549.5 KB |
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
/
Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ;
Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ;
Escudier, Bernard (Gustave Roussy) ;
Pal, Sumanta (City of Hope National Medical Center) ;
Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ;
Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ;
Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ;
Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ;
Park, Se Hoon (Samsung Medical Center) ;
Geertsen, Poul F. (Copenhagen University Hospital) ;
Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Markby, David W. (Exelixis, Inc) ;
Arroyo, Alan (Exelixis, Inc) ;
Dean, Mark (Exelixis, Inc) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
George, Daniel (Duke University Medical Center) ;
Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669
|
|
|
10.
|
|
10 p, 402.2 KB |
SEOM clinical guideline for treatment of kidney cancer (2017)
/
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ;
Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Campayo, M. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Chirivella, Isabel (Hospital Clínic Universitari (València)) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. [...]
2017 - 10.1007/s12094-017-1765-4
Clinical & Translational Oncology, Vol. 20 (november 2017) , p. 47-56
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
